

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : James W. West, Cameron S. Brandt, Stephen R. Jaspers
Serial No. : 10/684,149
Group Art Unit : 1644
Confirmation No. : 5157
Examiner : Schwadron, R. B.
Filed : October 10, 2003
For : PRODUCTION OF HOMOTRIMERIC FUSION PROTEINS
Date Submitted : December 20, 2007

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the examination of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

In accordance with 37 C.F.R. 1.97, the filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that a search has been conducted, nor shall it be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. Applicants believe that their invention as claimed is patentable over the references. It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Pursuant to 37 C.F.R. §1.97(e)(1), and 37 C.F.R. §1.704(d), the undersigned hereby states that each item of information contained in the information disclosure statement was

Supplemental Information Disclosure Statement dated: December 20, 2007

first cited in a communication from a foreign patent office in a counterpart foreign application, and this communication was received by an individual designated in §1.56(c) not more than thirty (30) days prior to the filing of the information disclosure statement.

While it is believed that no fee is due, please charge any fee or credit any overpayment to Deposit Account No. 26-0290.

Respectfully submitted,

A handwritten signature in cursive script that reads "Michelle L. Lewis".

Michelle L. Lewis
Registration No. 36,352

Customer No. 10117
ZymoGenetics, Inc.